TeleRanked

Run a telehealth clinic? Claim your profile on TeleRanked.

Business

Oura Agrees to Buy AI Primary Care Startup Counsel Health, Bringing Prescribing Telehealth Into the Smart Ring App

Oura said on November 10, 2026 that it signed a definitive agreement to acquire Counsel Health, an AI based primary care service whose board certified physicians can diagnose and prescribe. MedTech Dive and Healthcare Dive reported the all cash deal at $625 million, with Oura expecting it to close near the end of 2026. The agreement is signed but not yet closed.

The TeleRanked Editors·Updated November 15, 2026·7 min read

Quick answer

Oura, maker of the Oura smart ring, said on November 10, 2026 that it entered into a definitive agreement to acquire Counsel Health, an AI based primary care company whose board certified physicians can diagnose, order labs, and prescribe. MedTech Dive and Healthcare Dive reported the all cash transaction is valued at $625 million, and Oura expects it to close near the end of 2026. The deal is signed but not yet complete.

Key takeaways

  • →Oura announced on November 10, 2026 a definitive agreement to acquire Counsel Health, an AI native, physician supervised care platform.
  • →Oura did not state a price in its announcement. MedTech Dive and Healthcare Dive reported the transaction at $625 million in cash, expected to close near the end of 2026, subject to purchase price adjustments and customary closing conditions.
  • →Counsel pairs a medical AI with board certified physicians who can diagnose, treat, order labs, and prescribe when appropriate, and it is not intended for emergencies.
  • →Oura plans to offer Counsel inside the Oura app and combine it with biometric data from its rings. The companies have partnered since May 2026, and members can already try Counsel in Oura Labs.
  • →The deal moves Oura from wellness tracking into prescribing capable virtual care, and it follows Oura's existing obesity care partnership with Eli Lilly's LillyDirect, an overlap that has drawn questions about clinical independence.

Oura, the company best known for a sleep and activity tracking smart ring, is moving into virtual medical care. On November 10, 2026, it said it had entered into a definitive agreement to acquire Counsel Health, an AI based primary care service whose physicians can diagnose and prescribe.

The acquisition would place a prescribing capable telehealth service inside a consumer wearable used by millions of people, and it lands as device makers, drugmakers, and artificial intelligence companies move closer together in direct to consumer health.

What Oura announced

In a post on its company blog, Oura said it has entered into a definitive agreement to acquire Counsel Health and that the deal is expected to close near the end of this year. Oura did not disclose a price in the announcement. MedTech Dive and Healthcare Dive reported that the transaction is valued at $625 million in cash and is subject to purchase price adjustments and customary closing conditions. Oura's chief executive, Tom Hale, tied the purchase to access, saying getting care is increasingly difficult due to a confluence of higher healthcare costs and that, together, Oura and Counsel can bridge that gap.

A definitive agreement is a signed deal, not a completed one. Until the transaction closes, the two companies remain separate, and the terms can still be adjusted under the conditions the parties described.

What Counsel Health does

Counsel describes itself as an AI native, physician supervised primary care platform. Its medical AI, overseen by board certified physicians, answers health questions, helps interpret lab results, and suggests next steps. When appropriate, a Counsel physician can join to diagnose, treat, order labs, and prescribe. The company says the service is not for emergencies.

In practice, a user starts with the AI, which can take a medical history, pull in clinical guidelines, review records, and flag possible emergencies, and a human clinician can enter the conversation to provide a diagnosis, a prescription, or a referral. Counsel's founder and chief executive is Dr. Muthu Alagappan.

How it fits into the Oura app

Oura and Counsel have partnered since May 2026, and Oura members can already explore Counsel through Oura Labs, the company's early feature program. Oura said it plans to offer Counsel's platform within the Oura app and to pair it with the biometric data its rings collect, so that signals such as sleep, heart rate, temperature, and activity can inform the AI's guidance and a clinician's view. Counsel will keep working with its own enterprise customers, including health plans and health systems, after the deal.

Alagappan said the combination can give physicians context, biometric data, and member engagement, according to MedTech Dive.

From tracking to treating

The purchase marks Oura's clearest step from wellness measurement into clinical care. The company has been adding health features and striking deals with medical device makers such as ResMed and Dexcom. It also sought to raise up to $2.2 billion in an initial public offering in September 2026, then delayed the listing later that month, citing market uncertainty, according to MedTech Dive and Healthcare Dive.

Buying a service that can write prescriptions is a different kind of expansion from adding a glucose or breathing sensor. It puts Oura in the position of offering medical diagnosis and treatment, not just data, to a consumer base that bought a ring.

The Eli Lilly overlap

Oura already has a commercial foothold in prescription driven care. In June 2026, Oura and LillyDirect, Eli Lilly's direct to consumer telehealth platform, announced a collaboration on obesity care, with LillyDirect customers able to receive an Oura Ring sizing kit. Pharmaceutical Technology reported that tens of thousands of Oura users have logged use of GLP-1 receptor agonist drugs, the class that includes Lilly's weight loss and diabetes treatments, in the app.

Folding a prescribing capable service into a company that holds a standing obesity care partnership with a major drugmaker is the kind of arrangement that invites scrutiny over clinical independence, meaning whether recommendations made inside the app stay separate from commercial relationships. Oura has not described any change to how Counsel's clinicians would prescribe, and the companies have said the deal is still pending.

What this means for telehealth

The deal is another sign that wearables, artificial intelligence, and prescribing are converging in direct to consumer health. A device that continuously measures a wearer can now, in principle, route that person into an AI triage flow and then to a clinician who can prescribe, all inside one app. For patients, that promises faster access. It also raises the questions regulators and clinicians have pressed on virtual care generally: how a remote clinician confirms that a prescription is clinically appropriate, how AI generated guidance is supervised, and how prescribing decisions are documented and reviewed.

None of those questions are unique to Oura, and the acquisition does not change any prescribing rules. What it signals is scale: a prescribing telehealth service delivered through a mainstream consumer device rather than a standalone medical app.

Limits and what is not confirmed

  • The deal is signed but not closed. Oura described a definitive agreement expected to close near the end of 2026, subject to conditions.
  • Oura did not state a price in its announcement. The $625 million cash figure comes from MedTech Dive and Healthcare Dive, not Oura's own post.
  • Figures reported by other outlets, including Counsel's headcount and Oura's membership and revenue totals, were not confirmed in the sources used here and are left out.
  • This article is general information about a business transaction, not medical or legal advice. Anyone making care decisions should speak with a licensed clinician.

Frequently asked questions

Did Oura complete the Counsel Health acquisition?+

Not yet. On November 10, 2026, Oura announced a definitive agreement to acquire Counsel Health. The companies said the deal is expected to close near the end of 2026, subject to purchase price adjustments and customary closing conditions. Until it closes, the acquisition is signed but not final.

How much is Oura paying for Counsel Health?+

Oura did not disclose a price in its announcement. MedTech Dive and Healthcare Dive reported that the all cash transaction is valued at $625 million. Because Oura did not confirm a figure publicly, the amount should be read as reported by those outlets.

What is Counsel Health?+

Counsel is an AI native, physician supervised care service. Its medical AI, overseen by board certified physicians, answers health questions, helps interpret labs, and suggests next steps, and a physician can join to diagnose, treat, order labs, and prescribe when appropriate. Counsel says the service is not for emergencies.

Will Oura ring users be able to get prescriptions through the app?+

Oura said it plans to offer Counsel within the Oura app and to pair it with biometric data from its rings. Counsel's physicians can prescribe when appropriate, so a prescription is possible through the service, but prescribing decisions rest with the clinician and follow applicable telehealth and controlled substance rules. Members can already explore Counsel in Oura Labs.

How is Eli Lilly involved?+

Eli Lilly is not a party to the Counsel acquisition. Separately, Oura and Lilly's LillyDirect platform announced an obesity care collaboration in June 2026. Because Oura is now adding a prescribing capable care service while holding a commercial partnership with a drugmaker, the overlap has drawn questions about keeping clinical recommendations independent of those relationships. Oura has not described any change to how Counsel's clinicians prescribe.

Sources

  1. 1.Oura to Acquire Counsel Health (company announcement) · Oura
  2. 2.Oura makes bet on AI in healthcare with $625M Counsel Health buy · MedTech Dive
  3. 3.Oura makes bet on AI in healthcare with $625M Counsel Health buy · Healthcare Dive
  4. 4.Lilly's LillyDirect and Oura partner on obesity care · Pharmaceutical Technology

Related